On June 6, 2017, Accurexa Inc. entered into a license agreement pursuant to which Medisun Holdings Limited granted the Company a non-exclusive license to use Medisun's NK (Natural Killer) cell technology in the rest of the world from the date of License until the termination of the First License Agreement. Medisun has developed its NK cell technology for the treatment of cancer. The NK cell technology is currently clinically used to treat cancer patients at Medisun's network clinical facilities. The License provides that Medisun will provide to the Company any relevant technical advice and support from time to time as required by the Company during the Term.